Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +3.76%41 EPS without NRI is $0.90 as of Jun. 2026. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 157 Medical Diagnostics & Research companies, Interpace Biosciences ranks worse than 636942.04% on this metric.
Interpace Biosciences's earnings per share without non-recurring items for the
three
months ended in Jun. 2026 was $0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was $0.90.
During the past 12 months, Interpace Biosciences's average earnings per share (NRI) Growth Rate was 36.80% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Interpace Biosciences's EPS without NRI or its related term are showing as below:
During the past 13 years, Interpace Biosciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 70.30% per year. The lowest was -103.10% per year. And the median was 14.80% per year.
IDXG's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.7 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Interpace Biosciences (OTCPK:IDXG) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Interpace Biosciences EPS without NRI Related Terms
Interpace Biosciences EPS without NRI Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDXG vs PRPO, ADVB, BIOQ: EPS without NRI Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a EPS without NRI of $0.90 as of Jun. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #999999 out of 157 companies in the Medical Diagnostics & Research industry.
Is Interpace Biosciences' EPS without NRI too high?
Interpace Biosciences' current EPS without NRI is $0.90. The Medical Diagnostics & Research industry median EPS without NRI is 10.70. Interpace Biosciences' value of $0.90 is 91.6% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #999999 out of 157 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' EPS without NRI compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #999999 out of 157 companies for EPS without NRI. This places Interpace Biosciences in the lower half of its industry. The industry median EPS without NRI is 10.70. Interpace Biosciences' value of $0.90 is 91.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.70, based on 157 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current EPS without NRI of $0.90 is 91.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current EPS without NRI is $0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.63 — trading 714.5% above its estimated fair value. The current EPS without NRI is $0.90 and 91.6% below the Medical Diagnostics & Research industry median of 10.70. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current EPS without NRI is $0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.63 is trading 714.5% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
EPS without NRI: $0.90
GF Value™: $0.20 vs. price of $1.63 (714.5% above fair value)
Industry Position: 91.6% below the Medical Diagnostics & Research median (#999999 of 157)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
